BioCryst Pharmaceuticals, Inc. (BCRX)
$8.07-3.47%Close
SELLRECOVERY · day 5
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $2.1B
- Beta
- 0.55
- P/E (TTM)
- -5.61
- Short % float
- 12.79%
- Days to cover
- 4.6
- SI change
- -21.1%
- 1W
- +1.51%
- 1M
- -1.94%
- vs SPY 1W
- +1.65%
- vs SPY 1M
- -4.45%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 45
- VALUE
- 28
- GROWTH
- 24
- GARP
- 86
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC60.9%
REV YoY-
ROE101.6%
EPS YoY-
ROA-69.0%
GROSS24
OP-33
NET-41
[VALUATION]
P/E TTM-5.61
P/E FWD15.81
SECTOR PE20.34
INDUSTRY PE13.84
P/B-4.52
P/FCF-
EV/EBITDA-7.61
EV/EBIT-
PEG0.44
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO2.32
ND/EBITDA-
BETA0.55
Company news
FAQ
- What is LOPJLB’s current signal on BCRX?
- LOPJLB’s latest quantitative signal on BioCryst Pharmaceuticals, Inc. (BCRX) is SELL in a RECOVERY regime. Signals are updated daily.
- What market regime is BCRX in?
- BioCryst Pharmaceuticals, Inc. (BCRX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does BioCryst Pharmaceuticals, Inc. (BCRX) do?
- BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral…